From: COVID-19 does not influence functional status after ARDS therapy
 | n | Total cohort (n = 143) | n | COVID-19 ARDS (n = 100) | n | Non-COVID-19 ARDS (n = 43) |
---|---|---|---|---|---|---|
Barthel index baseline | 143 | Â | 100 | Â | 43 | Â |
 Independence (100) n (%) |  | 3 (2.1%) |  | 3 (3.0%) |  | 0 (0%) |
 Slight dependency (91–99) n %) |  | 0 (0%) |  | 0 (0%) |  | 0 (0%) |
 Moderate dependency (61–90) n (%) |  | 1 (0.7%) |  | 0 (0%) |  | 1 (2.3%) |
 Severe dependency (21–60) n (%) |  | 8 (5.6%) |  | 4 (4.0%) |  | 4 (9.3%) |
 Total dependency (0–20) n (%) |  | 131 (91.6%) |  | 93 (93.0%) |  | 38 (88.4%) |
Barthel index 28Â days | 126 | Â | 92 | Â | 34 | Â |
 Independence (100) n (%) |  | 25 (19.8%) |  | 23 (25%) |  | 2 (5.9%) |
 Slight dependency (91–99) n %) |  | 4 (3.2%) |  | 2 (2.2%) |  | 2 (5.9%) |
 Moderate dependency (61–90) n (%) |  | 16 (12.7%) |  | 10 (10.9%) |  | 6 (17.6%) |
 Severe dependency (21–60) n (%) |  | 12 (9.5%) |  | 7 (7.6%) |  | 5 (14.7%) |
 Total dependency (0–20) n (%) |  | 69 (54.8%) |  | 50 (54.3%) |  | 29 (55.9%) |
Barthel index 90Â days | 123 | Â | 89 | Â | 34 | Â |
 Independence (100) n (%) |  | 43 (35%) |  | 32 (36%) |  | 11 (32.4%) |
 Slight dependency (91–99) n %) |  | 3 (2.4%) |  | 2 (2.2%) |  | 1 (2.9%) |
 Moderate dependency (61–90) n (%) |  | 11 (8.9%) |  | 8 (9.0%) |  | 3 (8.8%) |
 Severe dependency (21–60) n (%) |  | 12 (9.8%) |  | 8 (9.0%) |  | 4 (11.8%) |
 Total dependency (0–20) n (%) |  | 54 (43.9%) |  | 39 (43.8%) |  | 15 (44.1%) |
Barthel index 180Â days | 98 | Â | 68 | Â | 30 | Â |
 Independence (100) n (%) |  | 34 (34.7%) |  | 24 (35.3%) |  | 10 (33.3%) |
 Slight dependency (91–99) n %) |  | 2 (2%) |  | 1 (1.5%) |  | 1 (3.3%) |
 Moderate dependency (61–90) n (%) |  | 6 (6.1%) |  | 4 (5.9%) |  | 2 (6.7%) |
 Severe dependency (21–60) n (%) |  | 3 (3.1%) |  | 0 (0%) |  | 3 (10%) |
 Total dependency (0–20) n (%) |  | 53 (54.1%) |  | 39 (57.4%) |  | 14 (46.7%) |